| Literature DB >> 29649579 |
Belén Alvarez-Alvarez1, Javier García-Seara2, Moisés Rodríguez-Mañero2, Diego Iglesias-Alvarez3, Jose L Martínez-Sande2, Rosa M Agra-Bermejo3, Xesús A Fernández López2, Laila González-Melchor2, Francisco Gude Sampedro4, Carla Díaz-Louzao4, José R González-Juanatey3.
Abstract
BACKGROUND: Cardiac resynchronization therapy (CRT) is indicated in symptomatic heart failure (HF) patients after achieving optimal medical therapy. However, there are still a large percentage of patients who do not respond to CRT. Malnutrition is a frequent comorbidity in patients with HF, and it is associated with a poorer prognosis. Here, we evaluate the nutritional status of patients assessed by Controlling Nutritional Status (CONUT) score and its association with structural remodeling and cardiovascular events.Entities:
Keywords: CONUT score; Cardiac resynchronization therapy; Heart failure; Malnutrition
Year: 2018 PMID: 29649579 PMCID: PMC6090074 DOI: 10.1016/j.ipej.2018.04.001
Source DB: PubMed Journal: Indian Pacing Electrophysiol J ISSN: 0972-6292
Baseline characteristics, reverse remodeling and clinical response according CONUT Score.
| Overall n = 302 | CONUT 0-1 | CONUT 2-4 | CONUT ≥5 | ||
|---|---|---|---|---|---|
| Age, (years) | 70 ± 10 | 68 ± 10 | 71 ± 9 | 73 ± 8 | |
| Male, n(%) | 234(77.5) | 109(73.6) | 79(79.8) | 46(83.6) | |
| NYHA class, n (%) | |||||
| II | 77(25.5) | 43(29.1) | 21(21.2) | 13(23.6) | |
| III | 210(69.5) | 101(68.2) | 73(73.7) | 36(65.5) | |
| IV | 15(5.0) | 4(2.7) | 5(5.1) | 6(10.9) | |
| Ischemic etiology, n (%) | 108(35.8) | 41(27.7) | 41(41.4) | 26(47.3) | |
| DM, n (%) | 74(24.5) | 30(20.3) | 28(28.3) | 16(29.1) | |
| BMI | 28 ± 4 | 28 ± 5 | 28 ± 4 | 28 ± 4 | |
| GFR, ml/(min x 1.73m2) | 61.2 ± 23.9 | 67.5 ± 54.9 | 54.4 ± 21.3 | 56.2 ± 21.7 | |
| Sodium, mmol/l | 138 ± 4 | 139 ± 3 | 138 ± 4 | 137 ± 4 | |
| Hemoglobine, g/dl | 13.2 ± 1.7 | 13.6 ± 1.4 | 13.0 ± 1.9 | 12.4 ± 1.9 | |
| AF, n (%) | 114(37.7) | 52(35.1) | 36(36.4) | 26(47.3) | |
| CRT-D, n (%) | 158(52.3) | 87(58.8) | 46(46.5) | 25(54.5) | |
| LBBB, n (%) | 186(61.6) | 90(60.8) | 62(62.6) | 34(61.8) | |
| QRS width, ms | 162 ± 26 | 161 ± 24 | 162 ± 25 | 165 ± 31 | |
| LVESV, ml | 166 ± 61 | 163 ± 63 | 162 ± 56 | 182 ± 62 | |
| LVEF, % | 27 ± 7 | 27 ± 7 | 27 ± 7 | 26 ± 8 | |
| LAd, mm | 49 ± 9 | 48 ± 7 | 49 ± 10 | 52 ± 9 | |
| ACEI/ARB, n(%) | 262(86.8) | 135(91.2) | 82(82.8) | 45(81.8) | |
| BB, n(%) | 254(84.1) | 121(81.8) | 86(86.9) | 47(85.5) | |
| MRA, n(%) | 144(47.7) | 71(48.0) | 46(46.5) | 27(49.1) | |
| LVEF FU, % | 39 ± 13 | 41 ± 13 | 39 ± 12 | 34 ± 12 | |
| Δ LVEF, % | 12 ± 13 | 14 ± 14 | 12 ± 12 | 8 ± 11 | |
| Δ LVEF > 5%, n (%) | 214(63.1) | 111(68.1%) | 72(67.9%) | 31(53.4%) | |
| LVESV FU | 100 ± 57 | 100 ± 57 | 106 ± 55 | 146 ± 75 | |
| Δ LVESV, ml | −50 ± 62 | −57 ± 61 | −52 ± 57 | −25 ± 68 | |
| ΔLVESV>15%, n (%) | 180(78.3) | 96(88.1%) | 61(84.7%) | 23(62.2%) | |
| LAd FU, mm | 47 ± 10 | 46 ± 9 | 46 ± 10 | 52 ± 8 | |
| ΔLAd FU | −1±9 | −1±9 | −1±9 | −1±10 | |
| Clinical Response, n (%) | 220(72.8) | 112(75.7) | 72(72.7) | 36(65.5) | |
| Clinical Response, n (%) | |||||
| -Worse | 4(1.3) | 0 (0.0) | 2(2.0) | 2(3.6) | |
| -No change | 78(25.8) | 36(24.3) | 25(25.3) | 17(30.9) | |
| -Improvement 1 class | 181(59.9) | 90(60.8) | 61(61.6) | 30(54.5) | |
| -Improvement 2 class | 39(12.9) | 22(14.9) | 11(11.1) | 6(10.9) | |
ACEI/ARB: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; AF: atrial fibrillation; BB: beta-blockers; BMI: Body Mass Index; CRT-ICD: Cardiac Resynchronization Therapy Defibrillator; DM: diabetes mellitus; FU: Follow-up; GFR: Glomerular Filtration Rate; LAd: Left atrium diameter; LBBB: Left bundle branch block; LVEF: Left ventricle eyeccion fraction; LVESV: left ventricular end systolic volume; MRA: mineralocorticoid receptor antagonist; NYHA: New York Heart Association; Δ: changes.
Fig. 1Cumulative survival free of HF/death according CONUT nutritional status pre CRT.
Multivariate Cox proportional hazards model for death/HF hospitalizations in patients with CRT.
| HR, CI 95% | ||
|---|---|---|
| Age | 1.03(1.01–1.05) | |
| Male | 1.86(1.15–3.02) | |
| Ischemic etiology | 1.16(0.77–1.76) | |
| AF | 1.21(0.80–1.81) | |
| GFR | 0.99(0.98–1.00) | |
| Sodium | 0.95(0.91–0.99) | |
| Hemoglobine | 0.98(0.87–1.10) | |
| CONUT | ||
| 0–1 | 1 | |
| 2–4 | 1.63(1.08–2.48) | |
| ≥5 | 1.88(1.15–3.06) | |
| LAd | 1.03(1.01–1.05) | |
| ACEI/ARB | 0.600(0.36–1.01) | |
Gender: 0: female, 1: male. Etiology: 0: non-ischemic, 1: ischemic. Functional class: NYHA II as a reference.
ACEI/ARB: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; AF: Atrial Fibrillation; GFR: Glomerular Filtration Rat; LAd: Left atrium diameter.
Differences in Baseline Characteristics between improvement and no improvement of CONUT post CRT.
| OVERALL n = 154 | CONUT NO IMPROVEMENT n = 90 | CONUT IMPROVEMENT n = 64 | ||
|---|---|---|---|---|
| Age, (years) | 72 ± 9 | 73 ± 8 | 71 ± 9 | |
| Male, n (%) | 67(43.5) | 41(45.6) | 26(40.6) | |
| NYHA class, n (%) | ||||
| II | 34(22.1) | 21(23.3) | 13(20.3) | |
| III | 109(70.8) | 62(68.9) | 47(73.4) | |
| IV | 11(7.1) | 7(7.8) | 4(6.2) | |
| CONUT prior CRT, n (%) | ||||
| CONUT 2-4 | 99(64.3) | 69(76.7) | 30(46.9) | |
| CONUT ≥5 | 55(35.7) | 21(23.3) | 34(53.1) | |
| Ischemic, n (%) | 67(43.5) | 41(45.6) | 26(40.6) | |
| DM, n (%) | 44(28.6) | 26(28.9) | 18(28.1) | |
| BMI | 28 ± 4 | 27 ± 4 | 29 ± 4 | |
| GFR, ml/(min x 1.73m2) | 55.1 ± 21.4 | 54.2 ± 21.5 | 56.3 ± 21.2 | |
| Sodium, mmol/l | 138 ± 4 | 138 ± 4 | 138 ± 2 | |
| Hemoglobine, g/dl | 12.8 ± 1.9 | 12.9 ± 2.0 | 12.7 ± 1.9 | |
| AF, n (%) | 62(40.3) | 34(37.8) | 28(43.8) | |
| CRT-D, n (%) | 71(46.1) | 39(43.3) | 32(50.0) | |
| LBBB, n (%) | 96(62.3) | 61(67.8) | 35(54.7) | |
| QRS width, ms | 163 ± 27 | 165 ± 25 | 161 ± 30 | |
| LVESV, ml | 169 ± 59 | 165 ± 56 | 176 ± 62 | |
| LVEF, % | 27 ± 7 | 27 ± 7 | 26 ± 7 | |
| LA, mm | 47 ± 10 | 49 ± 9 | 50 ± 11 | |
| ACEI/ARB, n (%) | 127(82.5) | 71(78.9) | 56(87.5) | |
| BB, n (%) | 133(86.4) | 76(84.4) | 57(89.1) | |
| MRA, n (%) | 73(47.4) | 45(50.0) | 28(43.8) | |
ACEI/ARB: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; AF: Atrial Fibrillation; BB: beta-blockers; BMI: Body Mass Index; CRT-ICD: Cardiac Resynchronization Therapy Defibrillator; DM: Diabetes Mellitus; GFR: Glomerular Filtration Rate; LA: Left atrium; LBBB: Left bundle branch block; LVEF: Left ventricle eyeccion fraction; LVESV: left ventricular end systolic volume; MRA: mineralocorticoid receptor antagonist; NYHA: New York Heart Association.
Fig. 2A. Cumulative survival free of death or HF hospitalizations according CONUT improvement after CRT; B. Cumulative survival free of death according CONUT improvement after CRT; C. Cumulative survival free of HF hospitalizations according CONUT improvement after CRT.
Multivariate Cox proportional hazards model for death/HF hospitalizations in patients with CRT.
| HR, CI 95% | ||
|---|---|---|
| Age | 1.04 (1.01–1.07) | |
| Male | 1.26 (0.81–1.98) | |
| Ischemic etiology | 1.32 (0.85–2.05) | |
| CRT-D | 0.67 (0.43–1.04) | |
| AF | 1.57(1.02–2.41) | |
| LBBB | 0.84 (0.5301.33) | |
| Δ QRS | 1.00 (0.99–1.01) | |
| Improve CONUT post CRT | 0.54(0.34–0.85) | |
| BB | 0.96 (0.51–1.83) | |
| MRA | 1.18(0.78–1.83) | |
| ACEI/ARB | 0.77 (0.40–1.48) |
Gender: 0: female, 1: male. Etiology: 0: non-ischemic, 1: ischemic.
ACEI/ARB: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; AF: Atrial Fibrillation; BB: beta-blockers; CRT: Cardiac Resynchronization Therapy; CRT-D: Cardiac Resynchronization Therapy Defibrillator; LBBB: Left bundle branch block; MRA: mineralocorticoid receptor antagonist.